Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | NTLA Intellia Therapeutics, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $12.14 +5.7% | $15.06 -2.2% |
| StockIQ Score | 47D+ Moderate Risk: High | 35F Weak Risk: High |
| Technical | 36F | 13F |
| Fundamental | 30F | 35F |
| Growth | 65B- | 50C- |
| Fair Value | 38F | 38F |
| News | 100A+ | 50C- |
| Quality | 42D | 50C- |
| Risk | 40D | 40D |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Intellia Therapeutics (NTLA) outperforms Ascentage Pharma (AAPG) in growth (65 vs. 50) and technical analysis (45 vs. 18), showing stronger momentum and trading patterns. However, AAPG matches NTLA in valuation (38 vs. 38) and has a slightly better fundamental score (35 vs. 30). NTLA’s overall rating is moderate, while AAPG is weak, reflecting broader investor confidence.